133 related articles for article (PubMed ID: 37970740)
1. Transfusion management in the era of magrolimab (Hu5F9-G4), an anti-CD47 monoclonal antibody therapy.
Singh N; Staves J; Storry JR; Dinoso J; Renard C; Doshi P; Johnson LDS; Westhoff CM; Murphy MF
Transfusion; 2023 Dec; 63(12):2377-2383. PubMed ID: 37970740
[No Abstract] [Full Text] [Related]
2. Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody).
Tan M; Zacher N; French R; Borosak M; Lennard S; Le Viellez A; Benson S; Daly J
Intern Med J; 2022 Dec; 52(12):2165-2171. PubMed ID: 36114660
[TBL] [Abstract][Full Text] [Related]
3. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
[TBL] [Abstract][Full Text] [Related]
4. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia.
Brierley CK; Staves J; Roberts C; Johnson H; Vyas P; Goodnough LT; Murphy MF
Transfusion; 2019 Jul; 59(7):2248-2254. PubMed ID: 31183877
[TBL] [Abstract][Full Text] [Related]
5. How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?
Murphy MF; Rajbhandary S; Carayiannis S; Cohn CS
Transfusion; 2024 May; ():. PubMed ID: 38767410
[TBL] [Abstract][Full Text] [Related]
6. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
7. Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing.
Mei Z; Wool GD
Hematol Oncol Clin North Am; 2019 Oct; 33(5):797-811. PubMed ID: 31466605
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal anti-CD47 interference in red cell and platelet testing.
Velliquette RW; Aeschlimann J; Kirkegaard J; Shakarian G; Lomas-Francis C; Westhoff CM
Transfusion; 2019 Feb; 59(2):730-737. PubMed ID: 30516833
[TBL] [Abstract][Full Text] [Related]
9. Two case reports involving therapeutic monoclonal anti-CD47 (Hu5F9-G4), it's effect on compatibility testing and subsequent selection of components for transfusion.
Reyland L; Dwight M; Bullock T; Latham T; Lord K; Wardle A; Palmer D; Eggington J; Callaghan T; Seals D; Kulkarni S
Transfus Med; 2020 Apr; 30(2):157-160. PubMed ID: 31914482
[No Abstract] [Full Text] [Related]
10. Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing.
Wei H; Cui Y; Ren D; Jiang X; Fu W; Mu S; Yang L; Chen J
Blood Transfus; 2024 Jan; 22(1):20-29. PubMed ID: 37847207
[TBL] [Abstract][Full Text] [Related]
11. Assessing and mitigating the interference of ALX148, a novel CD47 blocking agent, in pretransfusion compatibility testing.
Kim TY; Yoon MS; Hustinx H; Sim J; Wan HI; Kim H
Transfusion; 2020 Oct; 60(10):2399-2407. PubMed ID: 32820530
[TBL] [Abstract][Full Text] [Related]
12. A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.
Yu XY; Qiu WY; Long F; Yang XP; Zhang C; Xu L; Chang HY; Du P; Hou XJ; Yu YZ; Zeng DD; Wang S; Sun ZW
Biochimie; 2018 Aug; 151():54-66. PubMed ID: 29864508
[TBL] [Abstract][Full Text] [Related]
13. Impact of new myeloma agents on the transfusion laboratory.
Jones AD; Moayeri M; Nambiar A
Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
[TBL] [Abstract][Full Text] [Related]
14. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
Gholamin S; Mitra SS; Feroze AH; Liu J; Kahn SA; Zhang M; Esparza R; Richard C; Ramaswamy V; Remke M; Volkmer AK; Willingham S; Ponnuswami A; McCarty A; Lovelace P; Storm TA; Schubert S; Hutter G; Narayanan C; Chu P; Raabe EH; Harsh G; Taylor MD; Monje M; Cho YJ; Majeti R; Volkmer JP; Fisher PG; Grant G; Steinberg GK; Vogel H; Edwards M; Weissman IL; Cheshier SH
Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298418
[TBL] [Abstract][Full Text] [Related]
15. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
[TBL] [Abstract][Full Text] [Related]
16. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic BI; Lakhani N; Patnaik A; Shah SA; Chandana SR; Rasco D; Colevas AD; O'Rourke T; Narayanan S; Papadopoulos K; Fisher GA; Villalobos V; Prohaska SS; Howard M; Beeram M; Chao MP; Agoram B; Chen JY; Huang J; Axt M; Liu J; Volkmer JP; Majeti R; Weissman IL; Takimoto CH; Supan D; Wakelee HA; Aoki R; Pegram MD; Padda SK
J Clin Oncol; 2019 Apr; 37(12):946-953. PubMed ID: 30811285
[TBL] [Abstract][Full Text] [Related]
18. Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?
Bevel N; Thorpe M; Vanniasinkam T
Vox Sang; 2024 May; ():. PubMed ID: 38705581
[TBL] [Abstract][Full Text] [Related]
19. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity.
Qu T; Zhong T; Pang X; Huang Z; Jin C; Wang ZM; Li B; Xia Y
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450383
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD47 Agent Boosts Macrophage Activity in NHL.
Cancer Discov; 2019 Jan; 9(1):7-8. PubMed ID: 30464001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
